93 related articles for article (PubMed ID: 21245136)
1. Cardiac myocyte-specific ablation of follistatin-like 3 attenuates stress-induced myocardial hypertrophy.
Shimano M; Ouchi N; Nakamura K; Oshima Y; Higuchi A; Pimentel DR; Panse KD; Lara-Pezzi E; Lee SJ; Sam F; Walsh K
J Biol Chem; 2011 Mar; 286(11):9840-8. PubMed ID: 21245136
[TBL] [Abstract][Full Text] [Related]
2. Adenosine kinase attenuates cardiomyocyte microtubule stabilization and protects against pressure overload-induced hypertrophy and LV dysfunction.
Fassett J; Xu X; Kwak D; Zhu G; Fassett EK; Zhang P; Wang H; Mayer B; Bache RJ; Chen Y
J Mol Cell Cardiol; 2019 May; 130():49-58. PubMed ID: 30910669
[TBL] [Abstract][Full Text] [Related]
3. Ablation of Vitamin D Signaling in Cardiomyocytes Leads to Functional Impairment and Stimulation of Pro-Inflammatory and Pro-Fibrotic Gene Regulatory Networks in a Left Ventricular Hypertrophy Model in Mice.
Zupcic A; Latic N; Oubounyt M; Ramesova A; Carmeliet G; Baumbach J; Elkjaer ML; Erben RG
Int J Mol Sci; 2024 May; 25(11):. PubMed ID: 38892126
[TBL] [Abstract][Full Text] [Related]
4. Cardiac hypertrophy is not amplified by deletion of cGMP-dependent protein kinase I in cardiomyocytes.
Lukowski R; Rybalkin SD; Loga F; Leiss V; Beavo JA; Hofmann F
Proc Natl Acad Sci U S A; 2010 Mar; 107(12):5646-51. PubMed ID: 20212138
[TBL] [Abstract][Full Text] [Related]
5. lncRNA ZNF593-AS inhibits cardiac hypertrophy and myocardial remodeling by upregulating Mfn2 expression.
Nie X; Fan J; Wang Y; Xie R; Chen C; Li H; Wang DW
Front Med; 2024 Jun; 18(3):484-498. PubMed ID: 38743133
[TBL] [Abstract][Full Text] [Related]
6. IL-12α deficiency attenuates pressure overload-induced cardiac inflammation, hypertrophy, dysfunction, and heart failure progression.
Bhattarai U; He X; Xu R; Liu X; Pan L; Sun Y; Chen JX; Chen Y
Front Immunol; 2023; 14():1105664. PubMed ID: 36860846
[TBL] [Abstract][Full Text] [Related]
7. Knockout of M-LP/Mpv17L, a newly identified atypical PDE, induces physiological afferent cardiac hypertrophy in mice.
Iida R; Ueki M; Yasuda T
Transgenic Res; 2023 Dec; 32(6):575-582. PubMed ID: 37851308
[TBL] [Abstract][Full Text] [Related]
8. ESCRT-III Component CHMP4C Attenuates Cardiac Hypertrophy by Targeting the Endo-Lysosomal Degradation of EGFR.
Liu A; Xie H; Tian F; Bai P; Weng H; Liu Y; Liu W; Tang L; You H; Zhou N; Shu X
Hypertension; 2023 Dec; 80(12):2674-2686. PubMed ID: 37846580
[TBL] [Abstract][Full Text] [Related]
9. TGFbeta inducible early gene-1 (TIEG1) and cardiac hypertrophy: Discovery and characterization of a novel signaling pathway.
Rajamannan NM; Subramaniam M; Abraham TP; Vasile VC; Ackerman MJ; Monroe DG; Chew TL; Spelsberg TC
J Cell Biochem; 2007 Feb; 100(2):315-25. PubMed ID: 16888812
[TBL] [Abstract][Full Text] [Related]
10. Unraveling the complexities of cardiac remodeling and hypertrophy - high-content screening and computational modeling.
Elrod JW; van Berlo JH
J Mol Cell Cardiol; 2014 Jul; 72():360-3. PubMed ID: 24742541
[No Abstract] [Full Text] [Related]
11. Protein Kinase A Is a Master Regulator of Physiological and Pathological Cardiac Hypertrophy.
Bai Y; Zhang X; Li Y; Qi F; Liu C; Ai X; Tang M; Szeto C; Gao E; Hua X; Xie M; Wang X; Tian Y; Chen Y; Huang G; Zhang J; Xiao W; Zhang L; Liu X; Yang Q; Houser SR; Chen X
Circ Res; 2024 Feb; 134(4):393-410. PubMed ID: 38275112
[TBL] [Abstract][Full Text] [Related]
12. A multiscale model of cardiac concentric hypertrophy incorporating both mechanical and hormonal drivers of growth.
Estrada AC; Yoshida K; Saucerman JJ; Holmes JW
Biomech Model Mechanobiol; 2021 Feb; 20(1):293-307. PubMed ID: 32970240
[TBL] [Abstract][Full Text] [Related]
13. Some Remarks on Cardiac Hypertrophy and Dilatation.
Flint A
N Am Medchir Rev; 1859 Nov; 3(6):1046-1052. PubMed ID: 38079752
[No Abstract] [Full Text] [Related]
14. Synexpression group analyses identify new functions of FSTL3, a TGFβ ligand inhibitor.
Robertson RD; Mukherjee A
Biochem Biophys Res Commun; 2012 Oct; 427(3):568-73. PubMed ID: 23022195
[TBL] [Abstract][Full Text] [Related]
15. Cardiac myocyte follistatin-like 1 functions to attenuate hypertrophy following pressure overload.
Shimano M; Ouchi N; Nakamura K; van Wijk B; Ohashi K; Asaumi Y; Higuchi A; Pimentel DR; Sam F; Murohara T; van den Hoff MJ; Walsh K
Proc Natl Acad Sci U S A; 2011 Oct; 108(43):E899-906. PubMed ID: 21987816
[TBL] [Abstract][Full Text] [Related]
16. Follistatin-like 3 mediates paracrine fibroblast activation by cardiomyocytes.
Panse KD; Felkin LE; López-Olañeta MM; Gómez-Salinero J; Villalba M; Muñoz L; Nakamura K; Shimano M; Walsh K; Barton PJ; Rosenthal N; Lara-Pezzi E
J Cardiovasc Transl Res; 2012 Dec; 5(6):814-26. PubMed ID: 22915069
[TBL] [Abstract][Full Text] [Related]
17. Activin type II receptor signaling in cardiac aging and heart failure.
Roh JD; Hobson R; Chaudhari V; Quintero P; Yeri A; Benson M; Xiao C; Zlotoff D; Bezzerides V; Houstis N; Platt C; Damilano F; Lindman BR; Elmariah S; Biersmith M; Lee SJ; Seidman CE; Seidman JG; Gerszten RE; Lach-Trifilieff E; Glass DJ; Rosenzweig A
Sci Transl Med; 2019 Mar; 11(482):. PubMed ID: 30842316
[TBL] [Abstract][Full Text] [Related]
18. Circulating Growth Differentiation Factors 11 and 8, Their Antagonists Follistatin and Follistatin-Like-3, and Risk of Heart Failure in Elders.
Kizer JR; Patel S; Ganz P; Newman AB; Bhasin S; Lee SJ; Cawthon PM; LeBrasseur NK; Shah SJ; Psaty BM; Tracy RP; Cummings SR
J Gerontol A Biol Sci Med Sci; 2024 Jan; 79(1):. PubMed ID: 37624693
[TBL] [Abstract][Full Text] [Related]
19. An integrated signature of extracellular matrix proteins and a diastolic function imaging parameter predicts post-MI long-term outcomes.
Koh HWL; Pilbrow AP; Tan SH; Zhao Q; Benke PI; Burla B; Torta F; Pickering JW; Troughton R; Pemberton C; Soo WM; Ling LH; Doughty RN; Choi H; Wenk MR; Richards AM; Chan MY
Front Cardiovasc Med; 2023; 10():1123682. PubMed ID: 37123479
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
